Compare Acadia Healthcare Company Inc (ACHC) vs Bristol-Myers Squibb Co (BMY) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Acadia Healthcare Company Inc vs Bristol-Myers Squibb Co — how do they compare? Acadia Healthcare Company Inc trades at $30.71 (market cap $2.94B), while Bristol-Myers Squibb Co trades at $57.82 (market cap $118.38B). The key difference: Bristol-Myers Squibb Co is far larger — about 40.3× Acadia Healthcare Company Inc's market cap, and Bristol-Myers Squibb Co pays a 4.35% dividend while Acadia Healthcare Company Inc pays none. Which is the better fit depends on your goals.
| ACHC | BMY | |
|---|---|---|
Market Cap | $2.94B | $118.38B |
Sector | Health | Health |
52-Week High | $31.92 | $62.37 |
52-Week Low | $11.68 | $42.60 |
Enterprise Value | $5.45B | $154.32B |
Dividend Yield | — | 4.35% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ACHC trades at $31.09, down 2.57% today but maintains a bullish technical outlook with strong moving average support. The company shows operational strength with three consecutive earnings beats, though profitability remains challenged with a -32.84% net margin. Analyst consensus is strongly bullish with 68% buy ratings, while recent news highlights the company's strategic shift toward profitability and rising behavioral health demand.
The stock presents a mixed opportunity with strong technical momentum and analyst support offset by persistent profitability challenges. Key catalysts include continued earnings outperformance and successful execution of the turnaround strategy, while risks center on margin pressures and high short interest that could limit upside potential.
Bristol Myers Squibb (BMY) trades at $57.97, down 0.28% today, with a bullish technical signal and consistent earnings beats. The company maintains strong profitability with a 15.01% net income margin and a 4.3% dividend yield. Recent news highlights its growth portfolio now comprising over 54% of revenues, though patent cliff concerns persist. Cash flow from operations remains robust at $14.16B for 2025, supporting dividend sustainability.
BMY offers value with a P/E of 15.88 below industry averages, but faces significant patent expiration risks that could pressure future revenues. Analyst consensus is mixed with a $64.33 price target suggesting 11% upside. The stock is a cash flow machine with upside potential if new drug pipelines deliver, though investors must weigh growth execution against legacy portfolio declines.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Acadia Healthcare Company Inc
Acadia Healthcare is a leading provider of behavioral healthcare services across the US and Puerto Rico. It operates a network of psychiatric hospitals, residential treatment centers, and clinics for mental health and addiction recovery.
Read more on ACHC →About Bristol-Myers Squibb Co
Bristol-Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Unlike some of its more diversified peers, Bristol has exited several nonpharmaceutical businesses to focus on branded specialty drugs, which tend to support strong pricing power.
Read more on BMY →
